about
Increased expression of PITX2 transcription factor contributes to ovarian cancer progressionOver-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesisTargeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cellsAMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activityEpigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancerFOXM1b, which is present at elevated levels in cancer cells, has a greater transforming potential than FOXM1c.Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancerTargeting AMPK signaling in combating ovarian cancers: opportunities and challenges.Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancerLY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.Zic2 synergistically enhances Hedgehog signalling through nuclear retention of Gli1 in cervical cancer cells.Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis.Epigenetic alteration of the metallothionein 1E gene in human endometrial carcinomas.Overexpression of the transcription factor ATF3 with a regulatory molecular signature associates with the pathogenic development of colorectal cancer.Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry.Correction: Reduced expression of AMPK-ß1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer.Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.ERBB2 mutation: A promising target in non-squamous cervical cancer.Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers.Novel Nuclear Partnering Role of EPS8 With FOXM1 in Regulating Cell ProliferationSIL/TAL1 recombination in adult T-acute lymphoblastic leukemia and T-lymphoblastic lymphomaPattern of T-cell receptor delta gene rearrangement by Southern blotting and polymerase chain reaction technique in Hong Kong Chinese patients with non-T-cell hematological malignanciesDUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancermiR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancerp53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer
P50
Q21090912-E8C908E8-75C3-454C-8E9D-589DEB35CB9DQ28279426-734BE974-8AC2-4C28-A587-01310A1441B1Q28484496-4E0E5E6A-C3DB-49B6-8AB7-1781F8E53324Q28484795-09C8719B-C43A-464F-BB9B-7A7E8DD33DB2Q33572313-8C6E7D7A-51B9-46D0-B7A7-96F17F16E6E0Q33590428-EF181E31-C33A-4D43-A934-1C486DB1B553Q36576225-652EB8F1-6A29-4093-8724-8944709988E1Q36926103-95D5CCD0-3455-4CC7-83AC-5CBDF1474960Q36949580-CC524A46-D691-41BD-9C41-AB0355B37F59Q37401513-969C59AE-3C9F-4087-A302-7E5F46EE5417Q39443626-2D37329D-BF1D-494E-A2C5-48D5D7BCF657Q39526958-5A6FEE85-5E66-4962-A7B7-14D6A83FA57EQ39715158-82915F18-8B23-4ABC-B1A4-7411388D985DQ39855727-92CED55E-E749-4C3A-83EA-12FA246543DDQ41470878-67FCE570-4B3E-42E7-9E18-5E5BE14122A9Q42376660-307783C2-52B5-4A82-B47F-BC8BEC917B4BQ45939013-E102EC7A-010D-4BBD-880E-BA2C4090A7ECQ46799064-F3421C45-78FF-430C-9AA3-F676F9D0A5DDQ49568845-70C8D57A-31C9-4B13-9DF9-31BEFCF9DD5BQ52584568-4090512F-9708-444A-A07D-0A27F02AAD64Q53319306-5AEAAD5E-3E05-4D76-AA29-33614266B12BQ55394623-680131E2-8D90-480F-9690-849159E623DBQ64075503-B102B6D1-9AF6-4EAD-9C3B-4229F1C52A12Q70866346-BD0F4EA1-47A5-41A2-9BAD-00A21E3395C0Q71697077-CE04D383-CA8B-45A9-A156-B89E04E67060Q88500255-74CFB5DD-D919-425E-8D1C-E840789467C6Q91239726-7CE4E302-44FF-41BE-85A0-18D228B8B9FFQ93114379-8E6C02C6-B27F-47DF-807E-CB2EBF999FC3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David W Chan
@ast
David W Chan
@en
David W Chan
@es
David W Chan
@nl
type
label
David W Chan
@ast
David W Chan
@en
David W Chan
@es
David W Chan
@nl
prefLabel
David W Chan
@ast
David W Chan
@en
David W Chan
@es
David W Chan
@nl
P106
P1153
26533900600
P21
P31
P496
0000-0002-6951-3467